GlassScriptPhysician profile
Erin M Papp
NPI 1811126154
$4,927.42
in general payments reported to CMS, 2019-2025
13 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $117 · 2021: $220 · 2022: $168 · 2023: $307 · 2024: $3,552 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,349 · Travel and Lodging: $1,234 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,349.19 |
| Travel and Lodging | $1,233.92 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,824.77 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $365.51 | 2019-2025 | Dailies Total1, Total30, Tryptyr |
| Coopervision INC. | $220.82 | 2019-2025 | Paragon Crt |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.29 | 2019-2021 | |
| Biotissue Holdings INC. | $115.28 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $55.06 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $51.00 | 2023-2025 | Infuse, Miebo |
| Lombart Brothers, INC. | $32.12 | 2019 | |
| Kala Pharmaceuticals, INC. | $30.64 | 2021 | |
| Lkc Technologies, INC. | $22.11 | 2025 | |
| Oyster Point Pharma, INC. | $19.18 | 2024 | Tyrvaya |
| Alcon Research LLC | $16.63 | 2019 | |
| Allergan, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Papp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.